European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention
Top Cited Papers
Open Access
- 16 January 2019
- journal article
- research article
- Published by Springer Science and Business Media LLC in The Journal of Headache and Pain
- Vol. 20 (1), 1-33
- https://doi.org/10.1186/s10194-018-0955-y
Abstract
Monoclonal antibodies acting on the calcitonin gene-related peptide or on its receptor are new drugs to prevent migraine. Four monoclonal antibodies have been developed: one targeting the calcitonin gene-related peptide receptor (erenumab) and three targeting the calcitonin gene-related peptide (eptinezumab, fremanezumab, and galcanezumab). The aim of this document by the European Headache Federation (EHF) is to provide an evidence-based and expert-based guideline on the use of the monoclonal antibodies acting on the calcitonin gene-related peptide for migraine prevention. The guideline was developed following the Grading of Recommendation, Assessment, Development, and Evaluation (GRADE) approach. The working group identified relevant questions, performed systematic review and analysis of the literature, assessed the quality of available evidence, and wrote recommendations. Where the GRADE approach was not applicable, expert opinion was provided. We found low to high quality of evidence to recommend eptinezumab, erenumab, fremanezumab, and galcanezumab in patients with episodic migraine and medium to high quality of evidence to recommend erenumab, fremanezumab, and galcanezumab in patients with chronic migraine. For several clinical questions, there was not enough evidence to provide recommendations using the GRADE approach and recommendations relied on experts’ opinion. Monoclonal antibodies acting on the calcitonin gene-related peptide are new drugs which can be recommended for migraine prevention. Real life data will be useful to improve the use of those drugs in clinical practice.Keywords
This publication has 56 references indexed in Scilit:
- Evidence-based guideline update: Pharmacologic treatment for episodic migraine prevention in adultsNeurology, 2012
- GRADE guidelines: 9. Rating up the quality of evidenceJournal of Clinical Epidemiology, 2011
- GRADE guidelines: 4. Rating the quality of evidence-study limitations (risk of bias)Journal of Clinical Epidemiology, 2011
- OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trialCephalalgia, 2010
- OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trialCephalalgia, 2010
- Migraine prevalence by age and sex in the United States: A life-span studyCephalalgia, 2010
- Chronic migraine in the populationNeurology, 2008
- Patterns of Diagnosis and Acute and Preventive Treatment for Migraine in the United States: Results from the American Migraine Prevalence and Prevention StudyHeadache: The Journal of Head and Face Pain, 2006
- Long‐Term Migraine Prevention With Topiramate: Open‐Label Extension of Pivotal TrialsHeadache: The Journal of Head and Face Pain, 2006